Andrew Tsai
Stock Analyst at Jefferies
(4.86)
# 349
Out of 4,512 analysts
162
Total ratings
62.9%
Success rate
30.8%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintained: Buy | $255 | $191.95 | +32.85% | 8 | Jul 13, 2026 | |
| ATAI AtaiBeckley | Maintained: Buy | $10 | $5.67 | +76.37% | 12 | Jul 7, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $100 | $84.09 | +18.92% | 10 | Jul 6, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $550 | $327.68 | +67.85% | 8 | Jun 30, 2026 | |
| HELP Cybin | Maintained: Buy | $22 | $6.68 | +229.34% | 2 | Jun 25, 2026 | |
| DFTX Definium Therapeutics | Rated: Buy | $35 | $45.98 | -23.88% | 4 | Jun 22, 2026 | |
| MRNA Moderna | Maintained: Hold | $45 | $67.44 | -33.27% | 7 | Jun 16, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $18 | $13.39 | +34.43% | 2 | May 14, 2026 | |
| ANRO Alto Neuroscience | Maintained: Buy | $35 | $27.80 | +25.90% | 8 | May 14, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $200 | $235.16 | -14.95% | 2 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $145 | $74.50 | +94.63% | 1 | Apr 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $100 | $67.30 | +48.59% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $30 | $17.96 | +67.04% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 | $5.85 | +28.21% | 1 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $0.9 | $0.2461 | +265.71% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $5 | $4.02 | +24.38% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $29.13 | +2.99% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $37.91 | -15.59% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $5.55 | +80.18% | 7 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 → $3 | $3.63 | -17.36% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $0.85 | $2.12 | -59.91% | 2 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.5 | $5.69 | n/a | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $46.69 | n/a | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 | $41.46 | n/a | 3 | Dec 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $0.5 | $9.85 | n/a | 9 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $13 | $6.24 | n/a | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $23.78 | n/a | 5 | Jun 24, 2024 |
Biogen
Jul 13, 2026
Maintained: Buy
Price Target: $255
Current: $191.95
Upside: +32.85%
AtaiBeckley
Jul 7, 2026
Maintained: Buy
Price Target: $10
Current: $5.67
Upside: +76.37%
BridgeBio Pharma
Jul 6, 2026
Maintained: Buy
Price Target: $100
Current: $84.09
Upside: +18.92%
Praxis Precision Medicines
Jun 30, 2026
Maintained: Buy
Price Target: $550
Current: $327.68
Upside: +67.85%
Cybin
Jun 25, 2026
Maintained: Buy
Price Target: $22
Current: $6.68
Upside: +229.34%
Definium Therapeutics
Jun 22, 2026
Rated: Buy
Price Target: $35
Current: $45.98
Upside: -23.88%
Moderna
Jun 16, 2026
Maintained: Hold
Price Target: $45
Current: $67.44
Upside: -33.27%
COMPASS Pathways
May 14, 2026
Maintained: Buy
Price Target: $18
Current: $13.39
Upside: +34.43%
Alto Neuroscience
May 14, 2026
Maintained: Buy
Price Target: $35
Current: $27.80
Upside: +25.90%
Axsome Therapeutics
May 1, 2026
Maintained: Buy
Price Target: $200
Current: $235.16
Upside: -14.95%
Apr 12, 2026
Initiated Coverage: Buy
Price Target: $145
Current: $74.50
Upside: +94.63%
Mar 9, 2026
Rated: Buy
Price Target: $65 → $100
Current: $67.30
Upside: +48.59%
Jan 12, 2026
Maintained: Buy
Price Target: $35 → $30
Current: $17.96
Upside: +67.04%
Dec 31, 2025
Maintained: Hold
Price Target: $7.5
Current: $5.85
Upside: +28.21%
Dec 17, 2025
Downgraded: Hold
Price Target: $15 → $0.9
Current: $0.2461
Upside: +265.71%
Dec 1, 2025
Maintained: Hold
Price Target: $3 → $5
Current: $4.02
Upside: +24.38%
Nov 24, 2025
Maintained: Buy
Price Target: $30
Current: $29.13
Upside: +2.99%
Nov 21, 2025
Initiated Coverage: Buy
Price Target: $32
Current: $37.91
Upside: -15.59%
Nov 11, 2025
Maintained: Buy
Price Target: $10
Current: $5.55
Upside: +80.18%
Aug 8, 2025
Maintained: Hold
Price Target: $2.5 → $3
Current: $3.63
Upside: -17.36%
Aug 6, 2025
Maintained: Hold
Price Target: $3 → $0.85
Current: $2.12
Upside: -59.91%
Mar 26, 2025
Maintained: Buy
Price Target: $8.5
Current: $5.69
Upside: n/a
Mar 12, 2025
Reiterated: Buy
Price Target: $40
Current: $46.69
Upside: n/a
Dec 7, 2024
Rated: Buy
Price Target: $35
Current: $41.46
Upside: n/a
Sep 18, 2024
Rated: Hold
Price Target: $3 → $0.5
Current: $9.85
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $75 → $13
Current: $6.24
Upside: n/a
Jun 24, 2024
Maintained: Buy
Price Target: $42
Current: $23.78
Upside: n/a